| KPRX Stock | | | USD 3.26 0.31 8.68% |
The current 90-days correlation between Kiora Pharmaceuticals and Tff Pharmaceuticals is 0.16 (i.e., Average diversification). The correlation of Kiora Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Kiora Pharmaceuticals Correlation With Market
Average diversification
The correlation between Kiora Pharmaceuticals and DJI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kiora Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Kiora Stock please use our
How to Invest in Kiora Pharmaceuticals guide.
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations | ELYM | | TFFP | | INBX | | TFFP | | INBX | | ELYM | | ELVN | | INBX | | ELVN | | TFFP |
| | High negative correlations |
Risk-Adjusted IndicatorsThere is a big difference between Kiora Stock performing well and Kiora Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kiora Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.